2,1,3-苯并噁二唑-5-基-硼酸 | 426268-09-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 中文名称: 2,1,3-苯并噁二唑-5-基-硼酸
• 中文别名: 苯并[c][1,2,5]恶二唑-5-硼酸
• 英文名称: benzo[c][1,2,5]oxadiazol-5-ylboronic acid
• 英文别名: benzo[c][1,2,5]oxadiazole-5-boronic acid；2,1,3-benzoxadiazol-5-ylboronic acid
• CAS: 426268-09-9
• 化学式: C₆H₅BN₂O₃
• mdl: MFCD07186239
• 分子量: 163.928
• InChiKey: CHYMBQMSEFLESI-UHFFFAOYSA-N

物化性质

• 沸点：
  374.7±52.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.27
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  79.4
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Benzo[c][1,2,5]oxadiazole-5-boronic acid
Synonyms: Benzofurazan-5-boronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Benzo[c][1,2,5]oxadiazole-5-boronic acid
CAS number: 426268-09-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H5BN2O3
Molecular weight: 163.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,1,3-苯并噁二唑-5-基-硼酸 在 四(三苯基膦)钯 、 铁粉 、 potassium carbonate 、 氯化铵 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 15.42h， 生成
  参考文献：
  名称：

  Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation

  摘要：

  Fatty-acid binding protein 4 (FABP4) is a promising therapeutic target for immunometabolic diseases, while its potential for systemic inflammatory response syndrome treatment has not been explored. Here, a series of 2-(phenylamino)benzoic acids as novel and potent FABP4 inhibitors are rationally designed based on an interesting fragment that adopts multiple binding poses within FABP4. A fusion of these binding poses leads to the design of compound 3 with an similar to 460-fold improvement in binding affinity compared to the initial fragment. A subsequent structure-aided optimization upon 3 results in a promising lead (17) with the highest binding affinity among all the inhibitors, exerting a significant anti-inflammatory effect in cells and effectively attenuating a systemic inflammatory damage in mice. Our work therefore presents a good example of lead compound discovery derived from the multiple binding poses of a fragment and provides a candidate for development of drugs against inflammation-related diseases.

  DOI：

  10.1021/acs.jmedchem.9b02107
• 作为产物：
  描述：

  5-溴-2,1,3-苯并恶唑 在 正丁基锂 、 硼酸三乙酯 、 四甲基乙二胺 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 反应 0.08h， 以45%的产率得到2,1,3-苯并噁二唑-5-基-硼酸
  参考文献：
  名称：

  Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor

  摘要：

  The synthesis of a 6,8-disubstituted 1,7-naphthyridine I and its characterization as a potent and selective phosphodiesterase type 4D inhibitor (IC50 = 1.5nM) are described. The compound inhibited TNFalpha-release from human peripheral blood mononuclear cells and was orally active in a model of adjuvant-induced arthritis in rats. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00720-x

文献信息

• Copper‐Catalyzed Radical Cross‐Coupling of Redox‐Active Oxime Esters, Styrenes, and Boronic Acids
  作者：Xiao‐Ye Yu、Quan‐Qing Zhao、Jun Chen、Jia‐Rong Chen、Wen‐Jing Xiao

  DOI：10.1002/anie.201809820

  日期：2018.11.19

  visible‐light‐driven, copper‐catalyzed three‐component radical cross‐coupling of oxime esters, styrenes, and boronic acids has been developed. Key steps of this protocol involve catalytic generation of an iminyl radical from a redox‐active oxime ester and subsequent C−C bond cleavage to generate a cyanoalkyl radical. Upon its addition to styrene, the newly formed benzylic radical undergoes coupling with a boronic‐acid‐derived

  已经开发了一种由可见光驱动，铜催化的肟酯，苯乙烯和硼酸的三组分自由基交叉偶联反应。该协议的关键步骤涉及从氧化还原活性肟酯催化生成亚胺基，然后进行C-C键裂解，生成氰基烷基。在将其添加到苯乙烯中后，新形成的苄基与硼酸衍生的ArCu II配合物偶联，从而获得含1,1-二芳基甲烷的烷基腈。
• Direct C–H Arylation of Thiophenes at Low Catalyst Loading of a Phosphine-Free Bis(alkoxo)palladium Complex
  作者：Yabo Li、Jingran Wang、Mengmeng Huang、Zhiwei Wang、Yusheng Wu、Yangjie Wu

  DOI：10.1021/jo402745b

  日期：2014.4.4

  An efficient phosphine-free direct C–H arylation of thiophenes at the α-position has been developed at low catalyst loading of bis(alkoxo)palladium complex (Cat.I, 0.1–0.2 mol %). The developed synthetic method can be applied to the synthesis of α-aryl/heteroaryl thiophenes from aryl or heteroaryl bromides in good to excellent yields and is compatible with the substrates bearing electron-donating or

  在双（烷氧基）钯配合物（Cat.I，0.1-0.2 mol％）的低催化剂负载下，已开发出一种有效的无磷的噻吩在α位上无膦直接CH芳基化的化合物。所开发的合成方法可用于从芳基或杂芳基溴化物以良好至优异的产率合成α-芳基/杂芳基噻吩，并且与带有给电子或吸电子基团的底物相容。噻吩2位和5位的反应性是相同的，并且在最佳条件下不依赖于空间位阻。该条件还可以以高转化率应用于其他杂环部分，例如苯并噻吩，苯并呋喃和吡咯。
• [EN] NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE<br/>[FR] DÉRIVÉS DE NAPHTHYRIDINE EN TANT QU'INHIBITEURS D'UN FACTEUR INDUCTIBLE PAR L'HYPOXIE
  申请人：FIBROGEN INC

  公开号：WO2012106472A1

  公开（公告）日：2012-08-09

  The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).

  本公开涉及能够抑制HIF羟化酶活性的新化合物、方法和组合物，从而增加缺氧诱导因子（HIF）的稳定性和/或活性。
• [EN] SMALL MOLECULE INHIBITORS OF DIHYDROFOLATE REDUCTASE<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE LA DIHYDROFOLATE RÉDUCTASE
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2016201219A1

  公开（公告）日：2016-12-15

  The disclosure relates to compositions and methods for the treatment of fungal, bacterial, and parasitic infections and inhibition of fungal, bacterial, and parasitic growth. In particular, such compositions include dihydrofolate reductase (DHFR) inhibitors that are able to bind to DHFR and inhibit its function, resulting in inhibition of DNA biosynthesis and reduced cell division. The disclosure features DHFR inhibitors having a diaminoquinazoline scaffold.

  该披露涉及用于治疗真菌、细菌和寄生虫感染以及抑制真菌、细菌和寄生虫生长的组合物和方法。具体来说，这些组合物包括能够结合到二氢叶酸还原酶（DHFR）并抑制其功能的DHFR抑制剂，从而抑制DNA合成和减少细胞分裂。该披露涉及具有二氨基喹唑啉骨架的DHFR抑制剂。
• Kinase antagonists
  申请人：Knight A. Zachary

  公开号：US20070293516A1

  公开（公告）日：2007-12-20

  The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tryosine kinase, PI3Kinase and mTOR, or PI3Kinase, mTOR and tryosine kinase.

  本发明提供了一种新型化合物，它们是 PI3 激酶、PI3 激酶和酪氨酸激酶、PI3 激酶和 mTOR，或者 PI3 激酶、mTOR 和酪氨酸激酶的拮抗剂。